下载掌阅APP，畅读海量书库
立即打开
Canadian biotech Medicago and GlaxoSmithKline are pushing for regulatory approval of the world's first plant-based vaccine after positive results against a number of coronavirus variants in a late-stage trial.
加拿大生物技术公司Medicago和葛兰素史克正在推动监管部门批准全球首个植物疫苗，此前该疫苗在针对多种新冠病毒变种的后期试验中取得了积极结果。
In a phase 3 randomised study in more than 24,000 adults across six countries, including the UK and the US, two doses of the Medicago vaccine, given in combination with GSK' s adjuvant, were 75.6 per cent effective against all variants in people without previous exposure to Covid-19. Omicron was not circulating during the study.
在一项对包括英国和美国在内的六个国家逾2.4万名成人进行的III期随机研究中，两剂Medicago疫苗与葛兰素史克辅药结合使用，对此前没有感染过新冠病毒的人群来说，对所有变种的有效性为75.6%。研究期间Omicron变种尚未传播。
Medicago's chief executive told the Financial Times that a “key differentiator” of the study was that it took place at a time when variants were in circulation, in contrast with most large studies that read out late last year, when the ancestral coronavirus was dominant. The vaccine uses plants to express the protein needed — it would be the world' s first plant-based vaccine.
Medicago首席执行官对英国《金融时报》表示，这项研究的一个“关键区别”在于，它发生在病毒变种传播时期。这种疫苗使用植物来表达所需的蛋白质，它将是全球首款植物疫苗。